Article

Active ingredient in eye pain treatment passes toxicology tests

AlphaRx Inc. reported positive toxicology data for ALRX IM, an indomethacin ester and the active ingredient in Binoxan. Binoxan is a topical, non-acidic, non-steroidal anti-inflammatory pro-drug in a colloidal formulation, intended to treat ocular inflammation, eye pain, and photophobia.

With superior anti-inflammatory, analgesic, and antipyretic properties, indomethacin is normally administered in capsular form for the treatment of systemic inflammatory diseases.

The sodium salt of indomethacin can be injected intravenously or used topically for the treatment of inflammatory conditions of the eye. Indomethacin esters have comparable biologic activity to standard indomethacin formulations in animal studies, but are substantially less toxic and less irritating than the existing non-steroidal therapy.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.